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Outcome measure Emerging evidence
Disease-oriented evidence
Blood pressure lowering in monotherapy Aliskiren as monotherapy is effective for treatment of hypertension and may be as effective
as an ARB
Blood pressure lowering in combination therapy Pilot trials demonstrate efficacy in combination with valsartan in normotensive individuals
Renal-protective effect No evidence
Patient-oriented evidence
Tolerability Aliskiren is highly tolerable and is probably as well tolerated as an ARB. Useful in patients
who cannot tolerate other drugs, especially ACE inhibitors
Adherence Aliskiren’s high tolerability and adherence in phase II suggest patients will adhere to aliskiren
therapy to the same extent as with an ARB
continued overleaf…
Blood pressure lowering in other categories of patient (i.e. severe
hypertension, elderly, different races, children)
No evidence
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Abstract
Introduction: Aliskiren is the first in a new class of antihypertensive drugs that inhibits the conversion of angiotensinogen to angiotensin I
by renin, thereby inhibiting production of angiotensin II, the key mediator in the regulation of body fluid volume and blood pressure. Aliskiren
is currently in phase III trials as monotherapy and phase II as combination therapy in patients with mild-to-moderate hypertension, and in
phase II trials in patients with diabetic nephropathy.
Aims: The aim of this review is to evaluate the emerging evidence for use of aliskiren in patients with hypertension and to predict its
preliminary place in therapy in clinical outcome terms. All randomized, controlled clinical trials of aliskiren (evidence level 2) were included
for analysis of efficacy with the selected outcomes of blood pressure lowering, tolerability, and adherence; all other publications were
excluded.
Evidence review: The available level 2 evidence, although limited to phase II trials, suggests that aliskiren is effective at lowering blood
pressure, an accepted surrogate outcome of morbidity and mortality, in patients with mild-to-moderate uncomplicated essential
hypertension. Preliminary evidence suggests aliskiren is as effective as the angiotensin receptor blocker irbesartan, but more studies are
needed. The available evidence also suggests that aliskiren is well tolerated and that patients exhibit good adherence to therapy. Aliskiren’s
effect on outcomes such as all-cause mortality, reduction in cardiovascular mortality, and reduction in cardiovascular events in patients with
mild-to-moderate essential hypertension as well as in special patient populations, remains to be determined.
Clinical potential: The evidence available regarding aliskiren’s effect on outcomes, including blood pressure, tolerability, and adherence,
supports its use in patients with mild-to-moderate hypertension. Although there is some preliminary evidence from small pilot trials, the use
of aliskiren in combination with other antihypertensives, and the use of aliskiren in other patient populations, cannot be recommended
without further evidence. 
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     Scope, aims, and objectives
Aliskiren (Novartis) is the first in a new class of antihypertensive
drugs called renin inhibitors that inhibit the conversion of
angiotensinogen to angiotensin I by renin. Renin inhibition blocks
production of angiotensin II, a key mediator in the regulation of
body fluid volume and blood pressure.
The objective of this article is to review the available evidence,
limited to phase II trials and pilot trials, for the use of aliskiren in
patients with hypertension, evaluating its effects on available
measured outcomes including blood pressure, adherence, and
tolerability. In addition, this article will provide an overview of the
disease, current treatment options, and pharmacoeconomic
considerations regarding antihypertensive drugs. Finally, given the
available outcomes evidence a discussion of aliskiren’s preliminary
place in therapy will be presented.
Methods
Literature searches were conducted on January 31, March 2, and
May 8, 2005 in the databases listed below. The search terms were
“aliskiren” and “SPP100” with no search tags unless otherwise
stated. Results were limited to English-language articles only. No
date limitations were imposed unless otherwise noted.
• PubMed, www.ncbi.nlm.nih.gov/entrez, 1966 to date 
• EMBASE, www.datastarweb.com, 1974 to date
• Database of Abstracts of Reviews of Effectiveness (DARE), NHS
Economic Evaluations Database (NHSEED), Health Technology
Assessment (HTA), www.york.ac.uk/inst/crd/darehp.htm   
• NHS HTA, www.ncchta.org
• National Guidelines Clearinghouse, www.guideline.gov
• National Institute for Health and Clinical Excellence (NICE),
www.nice.org.uk
• Cochrane Database of Systematic Reviews, www.cochrane.org
• Clinical Evidence, www.clinicalevidence.com
• American Society for Hypertension (ASH) abstract database,
www.abstracts2view.com/ash/
After removal of duplicates a total of 28 citations were identified
from PubMed, EMBASE, and ASH; no additional citations were
identified from the other databases. Records were manually
reviewed and 22 citations were excluded: animal studies (n=1),
nonsystematic reviews (n=12), and citations that mentioned
aliskiren but did not investigate its clinical use (n=9). No systematic
reviews of aliskiren have been published.
Inclusion criteria for the outcomes analysis of aliskiren used an
accepted scale of hierarchy of evidence (see Editorial Information
on inside back cover). All randomized, controlled clinical trials of
aliskiren (evidence level 2) were included (Table 1).
Introduction
Aliskiren is an oral antihypertensive drug that inhibits the
conversion of angiotensinogen to angiotensin I by renin, the first
step of the renin-angiotensin system (RAS) and a rate-limiting step
in the production of angiotensin II (Fig. 1). Angiotensin I is then
metabolized by angiotensin-converting enzyme (ACE) and other
enzymes to yield angiotensin II, a key mediator in the regulation of
body fluid volume and blood pressure. Angiotensin II controls body
fluid volume both directly by stimulating sodium reabsorption in the
proximal tubule of the kidney, and indirectly through stimulation of
aldosterone release. Angiotensin II is also a potent vasoconstrictor
that acts on arterioles to increase systemic blood pressure.
Inhibitors of other steps in the RAS pathway (Fig. 1), including ACE
inhibitors that block the conversion of angiotensin I to angiotensin
II and angiotensin receptor blockers (ARBs) that inhibit binding of
angiotensin II to type I angiotensin II receptors (AT-1), are currently
in clinical use as antihypertensive agents.
Research suggests that hypertension is related to vascular
damage, oxidative stress, and inflammation. Angiotensin II, one of
the key mediators in hypertensive disease, has been shown to act
as a proinflammatory mediator that increases vascular permeability,
promotes recruitment of inflammatory cells, and activates the
infiltrating immune cells (Touyz 2005). Angiotensin II has also been
shown to be involved in tissue repair and remodeling. 
The initial development of peptides as renin inhibitors began
around the same time as the development of ARBs, but problems
with oral bioavailability and cost prevented the clinical
Aliskiren | proof of concept review
© 2005 Core Medical Publishing Limited 14
Renin ACE
ACE
inhibitors ARBs
Arterioles 
(vasoconstriction)
Systemic blood
pressure
Body fluid volume
• Na+ reabsorption (kidney)
• Aldosterone release
Renin
inhibitors
Angiotensinogen Angiotensin II Angiotensin I
Fig. 1 | The renin-angiotensin system and pharmacotherapy
Outcome measure Emerging evidence
Decrease in major cardiovascular events No evidence
Decrease in mortality No evidence
Economic evidence
Cost effectiveness No evidence
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
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development of these earlier versions (Hollenberg & Fisher 1995;
Rongen et al. 1995; Fisher & Hollenberg 2001). These challenges
were overcome in the development of aliskiren through the use of
molecular modeling to design a small molecule drug with high
affinity and specificity for renin, better oral bioavailability, and a
long in vivo activity that had the potential for once-daily dosing
(Wood et al. 2003).
The attributes of renin inhibitors theoretically meet some of the
unmet needs in the treatment of patients with hypertension. By
inhibiting the first and rate-limiting step in the RAS system
(conversion of angiotensinogen to angiotensin I), aliskiren may
block the generation of angiotensin II more completely than ACE
inhibitors because there is no other substantive pathway for
angiotensin I production (Stanton 2003). In contrast, angiotensin
II, the major effector regulating blood pressure, can be
synthesized by alternative pathways (Wolny et al. 1997). Thus, a
more complete block of angiotensin II production via renin
inhibition could provide an advantage, perhaps increasing the
effectiveness of monotherapy. 
Aliskiren is currently in phase III trials for use as monotherapy and
in phase II trials in combination with valsartan, in patients with
uncomplicated mild-to-moderate hypertension. It is also being
studied in phase II trials in patients with hypertension and diabetic
nephropathy. Regulatory submission is expected to be filed in
early 2006.
Disease overview
Hypertension is a common disease that affects approximately
50 million people in the USA and about 1 billion people worldwide
(NHLBI 2004). The most common sequela of hypertension,
cardiovascular disease, is also the most frequent cause of death in
industrialized countries. The World Health Organization (WHO)
estimates that there are 7.1 million deaths (13% of total deaths)
annually due to complications of hypertension (WHO 2002). The
worldwide prevalence of hypertension is increasing; recent studies
estimate that the prevalence will increase by 60%, from 26.4% in
2000 to 29.2% by 2025 (Kearney et al. 2005). 
Although hypertension is a worldwide problem, sample surveys
from the 1990s have shown that its prevalence differs between
regions of the world. For example, in North America the prevalence
of hypertension is about 28% compared with about 44% in Europe
(Wolf-Maier et al. 2003). A recent analysis of surveys found that the
highest estimated prevalence for men was in Latin America and the
Caribbean (Mexico, Paraguay, and Venezuela) and for women in
former socialist economies (e.g. Slovakia); for both sexes the
lowest prevalence was in Asian regions (e.g. Korea, Thailand,
Taiwan) (Kearney et al. 2005). 
In addition to geographic differences, the prevalence of
hypertension also differs by race. For example, in the USA about
28% of Caucasians are hypertensive compared with 40–43% of
African-Americans (NCHS 2004). A recent study has shown,
however, that there are wide variations in hypertension prevalence
in both black (14–44%) and white (27–55%) populations
worldwide, and highlighted the importance of not overlooking
environmental factors that impact hypertension prevalence rates
(Cooper et al. 2005).
Some regional differences can be explained by genetic factors
and population demographics. In addition to race, family history
of hypertension confers significant additional risk, since the
genetic heritability of hypertension is about 30% (Agarwal et al.
2005). Age is another significant risk factor for developing
hypertension. Data from the Framingham Heart Study show that
the residual lifetime risk for developing hypertension in a
normotensive, 55-year-old person is 90% (Vasan et al. 2002).
Obesity is also a significant risk factor.
Awareness, treatment, and control of hypertension remain
significant challenges. Most people with hypertension are
undiagnosed, untreated, or undertreated, despite educational
campaigns and the availability of many generally well-tolerated
antihypertensive drugs. In the USA, data from the National
Health and Nutrition Examination Survey (NHNES) found that
30% of people with hypertension were unaware of their
condition, 41% were not treated, and 66% of those with
hypertension were not well controlled (NHLBI 2004). Another
study among patients with hypertension found that 71% in the
USA, 83% in Canada, and more than 90% in Europe were not
well controlled (Wolf-Maier et al. 2004). 
However, for those patients who are appropriately treated,
effective blood pressure lowering has been shown to decrease the
incidence of stroke by between 30 and 39%, coronary heart
disease by 20%, and major cardiovascular events by 21–28%
(Neal et al. 2000). In patients with stage 1 hypertension (systolic
blood pressure 140–159 mmHg and/or diastolic blood pressure
90–99 mmHg), it has been estimated that a 12 mmHg reduction of
blood pressure for 10 years prevents one death for every 11
moderate-risk patients treated, while a similar blood pressure
reduction in higher risk patients with cardiovascular disease and
target organ damage prevents one death for every nine patients
treated (NHLBI 2004). 
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Table 1 | Evidence base included in the review
Category Full papers Abstracts
Initial search 26 1
records excluded 22 0
records included 4 1a
Additional studies identified 10
Level 1 clinical evidence 00
Level 2 clinical evidence 5 0
Level ≥3 clinical evidence 00
trials other than RCT 00
case reports 0 0
Economic evidence 0 0
aIncluded in the original review and later excluded because the same study was identified
later as a full paper.
RCT, randomized controlled trial
Number of recordsThe sequelae of hypertension can have a significant impact on
patient quality of life in those who are not well controlled.
Interestingly, although there is the perception of a substantial
adverse impact on quality of life arising from pharmacologic
treatment, this has not been borne out in the literature (Beto et
al. 1992; Boissel et al. 1995; Fletcher et al. 2002; Degl’Innocenti
et al. 2004). 
Given the prevalence of hypertension, it follows that its economic
and societal burdens are enormous. In economic terms, it is
estimated that the USA spends more than $US59.7 billion annually
on the direct and indirect costs of treating hypertension (AHA
2005). Expenditures related to hypertension as well as
cardiovascular complications and other diagnoses related to
hypertension were estimated to be $US108 billion in 1998 in the
USA (Hodgson & Cai 2001). In addition, the complexity of
antihypertensive care, such as patient visits to ensure treatment
adherence and the care issues associated with the adverse
outcomes associated with uncontrolled hypertension, in an
increasingly elderly Western population represents a significant
societal burden.
Current therapy options 
Evidence-based treatment guidelines for hypertension emphasize
the importance of lifestyle modifications, including weight loss in
the overweight or obese, reduction in dietary sodium intake,
applying the DASH (Dietary Approaches to Stop Hypertension)
diet, increasing physical activity, and limiting alcohol intake, as
the first step in treatment (Whitworth 2003; NHLBI 2004; Williams
et al. 2004). Lifestyle modification is indicated for all hypertensive
patients; however, it rarely reduces blood pressure sufficiently
and recent data underscore the importance of rapid blood
pressure control (Julius et al. 2004). Therefore pharmacotherapy
is generally started in most patients.
Current pharmacologic options for the treatment of hypertension
include diuretics, beta blockers, ACE inhibitors, ARBs,
aldosterone receptor blockers, calcium channel blockers, and
alpha-1 blockers, together with various combinations of these
drugs (Anon. 2003). Although there is debate over which drug to
use as initial therapy, it is generally accepted that the majority of
patients will not be well controlled on one drug and will require
multidrug therapy. In addition, outcome studies have shown that,
in general, regardless of drug choice, larger decreases in blood
pressure lead to larger reductions in cardiovascular risks
(Staessen et al. 2001; Turnbull 2003). 
The relatively recent conclusion of major clinical trials and the
publication of new systematic reviews have shed light but also
created debate regarding the comparative efficacy of various
antihypertensive therapies as measured by clinically relevant
outcomes (ALLHAT 2002; Dahlof et al. 2002; Messerli 2003;
Messerli & Weber 2003; Wing et al. 2003; Davis et al. 2004;  Julius
et al. 2004). The results from some of these clinical trials together
with systematic reviews (Messerli et al. 1998; Neal et al. 2000;
Staessen et al. 2001; Psaty et al. 2003; Turnbull 2003) have
prompted the release of new treatment guidelines from many
countries and organizations. These include updated guidelines
from the USA (NHLBI 2004), Canada (CHEP 2005), the
WHO/International Society of Hypertension (ISH) (Whitworth 2003),
the European Society of Hypertension/European Society of
Cardiology (ESH/ESC 2003), the British Hypertension Society
(Williams et al. 2004), and NICE (2004) (Table 2). The USA,
Canadian, European, and WHO guidelines have lower overall
thresholds for treatment of hypertension (≥140/90 mmHg except
patients in special categories) compared with a threshold of
≥160/100 mmHg in the British and NICE guidelines. In addition, the
British and NICE guidelines recommend a higher threshold
(≥140/90 mmHg) for treatment of patients with additional
morbidities, compared with a lower threshold (≥130/80 mmHg) in
the other guidelines. Finally, several of the guidelines encourage an
overall assessment of cardiovascular risk, rather than isolated
treatment of hypertension, something also emphasized in a recent
review (Jackson et al. 2005).
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Guideline Prehypertension Initial therapya Threshold for pharmacologic intervention (mmHg) SBP/DBP
Uncomplicated Special populationsb
USAc Yes Low-dose thiazide diuretic ≥140/90 >130/80
WHO/ISHd No Low-dose thiazide diuretic ≥140/90 ≥130/80
European Society of
Hypertension/European
Society of Cardiologye
No Not specified ≥140/90 ≥130–139/85–89
British Hypertension
Societyf
No Not specified ≥160/100 ≥140–159/90–99
Canadiang No Not specified ≥140/90 ≥130/80
NICEh No Low-dose thiazide diuretic ≥160/100 ≥140/90
aFor most patients with uncomplicated hypertension. fWilliams et al. 2004.
bFor patients with additional morbidities (see individual guidelines for details). gCHEP 2005.
cNHLBI 2004. hNICE 2004.
dWhitworth 2003. SBP/DBP, systolic/diastolic blood pressure.
eESH/ESC 2003.
Table 2 | Comparison of current hypertension guidelines
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It is notable that the USA guidelines have established a category
of “pre-hypertension,” defined as 120–139/80–89 mmHg, recom-
mending intervention with lifestyle modification, but not
pharmacotherapy; individuals 65 years and older in this category
are twice as likely to develop hypertension than those with lower
blood pressure (NHLBI 2004). The USA, NICE, and WHO/ISH
guidelines also include a highly debated endorsement of low-dose
thiazide diuretics for initial therapy (see Table 2).
All the guidelines emphasize the fact that many patients need
combination therapy for blood pressure control. To that end, a
randomized clinical trial directly comparing two different
combinations of drugs, benazapril/hydrochlorothiazide and
amlodipine/benazapril, began enrolling patients in 2003 with the
trial expected to conclude in 2008 (Jamerson et al. 2004). In
addition, the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT), which is comparing the efficacy of a calcium channel
blocker alone or in combination with an ACE inhibitor, with a beta
blocker with or without a diuretic in high-risk patients (Sever et al.
2001), was stopped early because of significant reductions in
moratlity with the calcium channel blocker/ACE inhibitor
combination (Anon. 2005).
Unmet needs
Despite the availability of many effective, well-tolerated drugs, a
significant proportion of treated hypertensive patients remain
uncontrolled and face serious morbidity and mortality as a
consequence. 
Adherence
Adherence to treatment regimens for hypertension remains a major
challenge and has been shown to be as low as 30% in some
studies (Degli Eposti & Valpiani 2004). Contributing factors for
nonadherence may include patient age, drug tolerability, the largely
asymptomatic nature of the disease, lack of patient education
regarding adverse outcomes, and the complexities of combination
drug regimens. 
Various studies of interventions aimed at improving adherence,
such as pharmacist and pharmacist/physician intervention, have
shown some positive effects on adherence and reduction in blood
pressure, including a lower visit cost per patient (Borenstein et al.
2003; Chabot et al. 2003). A review of adherence interventions
found that simplification of drug dosing regimens increased
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Level of evidence Once-daily drug dose
(mg) (n)
Duration  Results ± standard
deviation
Reference Comment
Mean ↓ ↓daytime
ambulatory SBP mmHg
2 Aliskiren 37.5 (45) 4 weeks 0.4±11.7 Stanton et al. 2003 No placebo arm; ANCOVA treatment effect,
P=0.0002
Aliskiren 75 (46) 5.3±11.3
Aliskiren 150 (44) 8±11
Aliskiren 300 (47) 11±11
Losartan 100 (44) 10.9±13.8
Least-squares mean
↓ ↓SBP/DBP mmHg
2 Aliskiren 150 (127) 8 weeks 11.4±1.3/9.3±0.8 Gradman et al. 2005  Low dose of irbesartan used; usual dose
150–300 mg; P<0.001 for all doses vs placebo
Aliskiren 300 (130) 15.8±1.2/11.8±0.8
Aliskiren 600 (130) 15.7±1.2/11.5±0.8
Irbesartan 150 (134) 12.5±1.2/8.9±0.7
Placebo (131) 5.3±1.2/6.3±0.8
Absolute change in
mean arterial pressure
4 h post-dose
2 Aliskiren 300 (12) 48 h 4.9±5.6 Azizi et al. 2004 Study population was mildly sodium-depleted
normotensive healthy volunteers; P<0.01 for all
treatments vs placebo 4 h post-dose 
Valsartan 160 (12) 6.6±5
Aliskiren 150/Valsartan 80
(12)
7.4±5.2
Placebo (12) 0.3±5.6
Table 3 | Aliskiren as monotherapy and in combination therapy: effects on blood pressure
                                    adherence between 8 and 19.6% (seven of nine studies);
motivational strategies increased adherence up to 23% (10 of 24
studies); and interventions using multiple techniques increased
adherence from 5 to 41% (eight of 18 studies) (Schroeder et al.
2004). The review concluded that reducing the number of daily
doses of medication seemed to be effective, and, while the
motivational and more complex interventions appeared somewhat
effective, there was a need for more carefully designed studies to
gauge the true impact of such strategies.
Tolerability
In addition to education and the complexities of antihypertensive
treatment regimens, treatment-related adverse effects may
contribute to poor adherence rates (Caro et al. 1999). While some
antihypertensive medications are very well tolerated, particularly
the ARBs, like all drugs antihypertensive therapies have adverse
effects that limit their utility in some patients (Anon. 2003),
particularly in specific patient populations. Therefore improvement
in tolerability remains a goal of future drug development. 
Multidrug therapy
A further unmet challenge in the pharmacotherapy of
hypertension is the reality that most patients need treatment with
more than one antihypertensive drug, which may lead to
additional adverse events and a further decrease in adherence.
This is particularly true in patients with chronic kidney disease
who often need more than two drugs to control their
hypertension. Therefore a drug that can be used in monotherapy
remains a goal of future drug development, although it is
questionable whether it can be realistically achieved. 
Given these unmet needs, although clinical outcome trials ideally
need to measure long-term mortality, they should first focus on the
extent of blood pressure reduction (which correlates well with long-
term outcomes), tolerability, and adherence to therapy.
Recent clinical trials and systematic reviews of trials have
emphasized that the magnitude of blood pressure reduction is the
most important contributor to decreasing morbidity and mortality in
patients with hypertension. Blood pressure is therefore an
acceptable surrogate outcome in preliminary short-term trials. 
Outcomes achieved with aliskiren in clinical
development 
Phase II trials of aliskiren in patients with uncomplicated mild-to-
moderate hypertension are complete. The outcomes studied
include blood pressure reduction with use in monotherapy or in
combination with ARBs (pilot study only), and tolerability.
Blood pressure reduction with monotherapy
Aliskiren entered phase II trials for treatment of mild-to-moderate
hypertension following pilot studies that demonstrated treatment-
related reduction in angiotensin II levels (Hollenberg 2002;
Nussberger et al. 2002). There is now good phase II evidence that
aliskiren reduces blood pressure significantly compared with
placebo and that it is as effective as losartan and irbesartan (Table
3). Aliskiren 150 or 300 mg once daily were as effective as an ARB
(losartan 100 mg or irbesartan 150 mg) and significantly more
effective than placebo in reducing systolic and diastolic blood
pressure (Stanton 2003; Gradman et al. 2005).
This evidence from phase II trials is being verified in phase III trials,
including a trial outlined in Table 4, which should provide more level
2 evidence of the effectiveness of aliskiren as monotherapy on
blood pressure reduction in patients with mild-to-moderate
hypertension. Early results from these trials are not yet publicly
available.
Combination therapy with ARBs 
As most patients will require combination therapy it will be
important to evaluate the use of aliskiren in combination with other
antihypertensives. A small double-blind, placebo-controlled, pilot
study in 12 healthy, mildly sodium-depleted normotensive
volunteers examined the blood pressure lowering effects of single
doses of aliskiren 300 mg, valsartan 160 mg, a lower-dose
combination of the two drugs (aliskiren 150 mg and valsartan
80 mg), and placebo over a 48-h period (Azizi et al. 2004) (see Table
3). Four hours after treatment the lower-dose combination
treatment was as effective as the higher doses of each individual
drug and significantly lowered mean arterial pressure compared
with placebo. It should be emphasized that this was a pilot study
performed in normotensive volunteers. 
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Regimen Drug dosage n (total) Endpoint Duration Inclusion Exclusion Phase
Monotherapya Not stated 1064 Blood pressure
lowering
Not stated Mild-to-moderate
hypertension
Not stated III
Combination therapy
with valsartanb
Not stated Not stated Blood pressure
lowering
Not stated Mild-to-moderate
hypertension
Not stated II
Monotherapyc Not stated 496 Reduction in level
of protein in urine
Not stated Hypertension; elevated
serum protein levels;
confirmed type 2 diabetes
Certain diseases;
uncontrolled diabetes;
type 1 diabetes
II
aManufacturer press release, January 21, 2005.
bManufacturer press release, January 21, 2005.
cClinical Trials Database www.clinicaltrials.gov, accessed January 7, 2005.
Table 4 | Ongoing phase II and III randomized placebo-controlled trials with aliskiren (results from these trials are not yet
publicly available)
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To expand upon these preliminary results and to attempt to provide
evidence for use of aliskiren in combination therapy, a phase II trial in
patients with hypertension is examining the effects of treatment with
aliskiren and valsartan on blood pressure reduction (see Table 4).
Tolerability
The adverse effect profiles of current antihypertensive drugs can, in
part, be attributed to their sites of action or influence on
downstream mediators. For example, ACE affects the metabolism
of bradykinin and increases circulating and tissue concentrations of
substance P which, while contributing to the blood pressure
lowering effect of ACE inhibitors, may also cause troublesome
adverse effects including cough and angioedema that limit their
clinical use (Sunman & Sever 1993). Furthermore, blocking the RAS
with ARBs inhibits activation at the AT-1 subtype of angiotensin II
receptors, but since angiotensin II production is not blocked with
these drugs, it can still act at other sites. Aliskiren was developed
for its specificity and high affinity for renin thereby minimizing its
potential to act at alternative sites and theoretically minimizing
potential adverse effects. There are, however, local renin systems
where renin inhibition would not be desirable. For example, the
potential role of renin in the uterus may limit aliskiren’s use to
nonpregnant women (Shaw et al. 1989).
Evidence to date shows that aliskiren has a favorable adverse-
effect profile. Adverse effects associated with aliskiren were similar
in severity and incidence to those reported in patients treated with
losartan or irbesartan. The most commonly reported adverse
effects were fatigue or weakness, gastrointestinal disorders,
dizziness, and headache (Stanton 2003; Gradman et al. 2005). Of
those patients in whom a serious adverse event occurred or who
experienced an adverse event leading to withdrawal from the study,
one of two in the 37.5 mg aliskiren treatment arm, three of three in
the 75 mg aliskiren arm, two of three in the 300 mg aliskiren arm,
and one of three in the 100 mg losartan treatment arm had events
that may have been related to drug treatment; no patients in the
150 mg aliskiren arm had serious adverse events (Stanton 2003). In
another study, no serious adverse events were reported in patients
treated with aliskiren although one patient in the 600 mg treatment
arm stopped treatment because of elevated serum glutamic-
oxaloacetate transaminase (SGOT) and bilirubin and increased
diastolic blood pressure (Gradman et al. 2005). Furthermore, there
is evidence that aliskiren does not interact with warfarin (Dieterle et
al. 2004), a commonly co-prescribed drug particularly in elderly
patients with stroke risk, thus widening the proportion of patients
for whom aliskiren may be an option. 
Adherence
Adherence to antihypertensive therapy is a complex issue influenced
by many variables. One important factor is drug tolerability; drugs
associated with fewer adverse events have higher adherence and
persistence rates (Gerth 2002; Marentette et al. 2002). 
There is preliminary evidence from one study that adherence to
aliskiren therapy is high, averaging >95% in patients treated with
aliskiren (37.5, 75, 150, or 300 mg once daily) or losartan (100mg
once daily) for 4 weeks (Stanton 2003). These adherence measures
are not sufficient, however, and more studies are needed.
Resource utilization
The economic burden of treating hypertension is estimated to be
almost $US60 billion per year in the USA (AHA 2005). It is estimated
that the direct costs of drug therapy alone account for a large
proportion (about 50%) of the direct health costs of treating
hypertension (AHA 2005) and therefore cost-effectiveness ratios
are highly dependent on the choice of drug. 
However, drug acquisition cost is just one component for
consideration when evaluating the economic impact of treating
patients with hypertension. For example, studies have shown that
it is more cost-effective to treat more severe hypertension
compared with less severe disease, to treat older versus younger
patients, and to treat men versus women (Kawachi & Malcolm
1991; Stason 1991). 
There is no economic evidence for the use of aliskiren in the
treatment of hypertension. Economic studies show thiazide
diuretics are currently the most cost-effective agents because of
their low acquisition cost (Ramsey et al. 1999; Fischer & Avorn
2004) and aliskiren, due to the complexity of the manufacturing
process, is likely to have high acquisition costs. Nevertheless, there
is clearly a role for other commonly used drug classes, including
ACE inhibitors, ARBs, and calcium channel blockers in the
management of patients with hypertension based on better clinical
outcomes and patient preferences, e.g. tolerability. Cost-benefit
and cost-effectiveness comparisons of aliskiren with these drug
classes and in specific patient groups would therefore be welcome.
Furthermore, evidence related to any total cost-benefit of treatment
with aliskiren that included indirect costs, benefits in terms of
primary outcome prevention, and tolerability would provide a more
comprehensive view of its potential clinical utility.
Patient group/population 
To date, aliskiren has been studied in completed phase II trials and
ongoing phase III trials in patients with uncomplicated mild-to-
moderate hypertension. The existing evidence suggests that
aliskiren effectively lowers blood pressure and is associated with
good tolerability in this patient population.
However, hypertension is associated with many other comorbid
conditions and aliskiren is currently in phase II trials for treatment of
some of these populations, including diabetic nephropathy.
Treatment of hypertensive patients with and without diabetes with
ACE inhibitors or ARBs, inhibitors of the RAS, has been shown to
reduce progression to macroalbuminuria, reduce albuminuria, and
slow the progression of diabetic nephropathy independent of their
effects on arterial blood pressure (Lewis et al. 1993; GISEN Group
1997; Brenner et al. 2001; Lewis et al. 2001; Wright et al. 2002). 
Intraglomerular hypertension is thought to be a causative factor in
the progression of diabetic nephropathy as well as other chronic
nephropathies. Angiotensin II leads to constriction of afferent and
efferent glomerular arterioles; these effects are more prominent in
the efferent arteriole and the net result is an increase in glomerular
perfusion pressure. Both ACE inhibitors and ARBs, by inhibiting
angiotensin II production/action, decrease glomerular pressure
(Braam & Koomans 1996). Renin inhibitors including aliskiren
inhibit angiotensin II more completely than ARBs and ACE
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              inhibitors and therefore would be expected to more effectively limit
glomerular hypertension.
Indeed, it had been previously demonstrated, in earlier attempts at
renin inhibitor drug development, that these drugs cause renal
vasodilatory responses that are 50% greater than those seen with
ACE inhibitors (Hollenberg & Fisher 1995). Aliskiren could therefore
be more effective than existing therapies in treatment of diabetic
nephropathy in patients with or without hypertension, and
treatment of chronic kidney disease in patients with or without
diabetes, but to date there is no clinical evidence of its efficacy in
these patient populations. Furthermore, it is unclear whether more
complete angiotensin II blockade will lead to clinically relevant
incremental benefits. In addition glomerular filtration rate (GFR) is a
function of perfusion pressure and more complete blockade of
angiotensin II could lead to excessive decreases in GFR thereby
limiting the drug’s utility in patients with chronic kidney disease.
This is an important topic that warrants further studies.
The effectiveness of aliskiren in other high-risk patient populations,
such as those with severe hypertension or other cardiovascular risk
factors (chronic heart failure, previous myocardial infarction, stroke,
etc.) is unknown. Its effectiveness in other races (particularly
African-Americans), or special populations, such as the elderly and
children, also remains to be determined. 
Clinical potential
The existing clinical and economic burden of hypertension
underscores the significant needs that remain regarding
hypertension therapy. In an attempt to address some of these
needs, aliskiren was developed using rational drug design
principles. These principles indicate that theoretically aliskiren
should be as effective as current treatments, but with tolerability
and adherence advantages. 
There is strong preliminary evidence that aliskiren as monotherapy
given once daily is effective at reducing blood pressure in patients
with mild-to-moderate hypertension. In addition, there is some
evidence that aliskiren is comparable in efficacy to the ARBs
losartan and irbesartan. Clinical trials to date have also shown that
aliskiren is well tolerated, with adverse effect and adherence rates
comparable to ARBs. A good tolerability profile together with once-
daily administration may be expected to positively influence
adherence and quality of life, both of which can be significant
barriers to effective disease management in patients with
hypertension. Phase III trials are currently underway, which may
attempt to confirm these phase II data.   
For patients whose blood pressure can be controlled with single-
agent therapy, aliskiren may offer another well-tolerated, effective
alternative, but most patients with hypertension eventually need a
second antihypertensive drug. There is some evidence that
aliskiren combined with an ARB is effective in reducing blood
pressure. To date, one small, short-term (48 h) published pilot study
has shown that aliskiren effectively lowers blood pressure when
used in combination with the ARB valsartan in normotensive
individuals. Phase II trials in patients with mild-to-moderate
hypertension are currently underway (see Table 4).
In addition, if current phase II trials and future phase III trials in
patients with diabetic nephropathy provide clinical evidence of its
effectiveness, then aliskiren might prove to be of significant benefit
in these patients. Further evidence will therefore be needed to
demonstrate aliskiren’s effectiveness in this and other patient
groups, such as those with severe hypertension, the elderly, and
those with other risk factors, e.g. chronic heart failure and chronic
kidney disease. 
There is strong phase II evidence that aliskiren effectively lowers
blood pressure and blood pressure reduction is a valid predictor of
reduced mortality and cardiovascular events. On this basis,
although there are currently no long-term outcome data with
aliskiren on its effects on mortality and/or major cardiovascular
events, the evidence regarding its effect on blood pressure lowering
suggests that it is likely to be effective in reducing mortality.
Evidence suggests that treatment with the other RAS inhibitors,
ACE inhibitors, or ARBs, can have positive cardiovascular effects
that are independent of blood pressure control. Therefore aliskiren
has the potential to have similar effects, acting as it does on the first
step in the RAS pathway, effectively blocking the production of
angiotensin II. 
The precise economic impact of aliskiren is still unclear. However, if
its good tolerability profile and effectiveness are confirmed in phase
III studies, aliskiren may be a cost-effective option in the treatment
of hypertension, especially in patient populations where it may
prove to have a therapeutic advantage, e.g. patients with diabetic
nephropathy.
In summary, the available outcomes evidence for aliskiren from
phase II trials is encouraging and shows that it is effective in
patients with mild-to-moderate hypertension in monotherapy and
possibly as effective an ARB. Moreover, if the evidence from phase
II and III trials of aliskiren in combination therapy demonstrates an
antihypertensive effect of similar magnitude to existing combination
drugs, this in addition to its good tolerability profile and once-daily
dosing will support its use.
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